Double immunotherapy attack on aggressive lung cancer
NCT ID NCT05903092
Summary
This study is testing whether adding two immunotherapy drugs (monalizumab and durvalumab) to standard chemotherapy helps people with small cell lung cancer live longer without their cancer getting worse. It includes two groups: people with newly diagnosed advanced cancer and people who have already finished initial chemo-radiation. The trial is currently suspended and was designed for 84 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Center (Wayne State University)
Detroit, Michigan, 48201, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.